21.57 USD
↘ 1.30 (5.68%)AT CLOSE (11:59 AM EDT)
Avalo Therapeutics, Inc. Common Stock
AVTXNASDAQ • USD
21.38
↘ 0.19 (0.88%)
POST MARKET (AS OF 07:46 PM EDT)
Post Market
AS OF 07:46 PM EDT
21.38
↘ 0.19 (0.88%)
Market: CLOSED
Open?$22.74
High?$22.97
Low?$20.98
Prev. Close?$22.87
Volume?1.8M
Avg. Volume?1.8M
VWAP?$21.45
Rel. Volume?1.00x
Bid / Ask
Bid?$21.15 × 400
Ask?$22.70 × 500
Spread?$1.55
Midpoint?$21.92
Valuation & Ratios
Market Cap?661.5M
Shares Out?26.7M
Float?21.2M
Float %?86.6%
P/E Ratio?N/A
P/B Ratio?7.97
EPS?-$2.71
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Address
1500 LIBERTY RIDGE DRIVE
WAYNE, PA 19087
Phone: 410-522-8707
WAYNE, PA 19087
Phone: 410-522-8707
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?8.13Strong
Quick Ratio?8.13Strong
Cash Ratio?1.23Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score58/100
P/E?N/A▾
P/B?7.97FAIR▾
P/S?11,212.14HIGH▾
P/FCF?N/A▾
EV/EBITDA?-8.9CHEAP▾
EV/Sales?10,943.36HIGH▾
Returns & Efficiency
ROE?-94.2%WEAK▾
ROA?-67.2%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$645.7M
Fundamentals ratios updated end of day